• Tel: 858.663.9055
  • SeparatorEmail: info@nsjbio.com
  • Tel: 858.663.9055
  • Email: info@nsjbio.com
Home >> Antibodies >> Recombinant BRAF Antibody / / N-Terminal Region

Recombinant BRAF Antibody / / N-Terminal Region [clone RM308] (R20328)

  Catalog No Formulation Size Price (USD)  
Image R20328-0.1ML Antibody in PBS with 50% Glycerol, 1% BSA and 0.09% sodium azide 100 ul 339
Western blot testing of human K562 cell lysate with recombinant BRAF antibody at 1:100 dilution. Predicted molecular weiight ~84 kDa.
IHC testing of formalin fixed and paraffin embedded human kidney tissue with recombinant BRAF antibody at 1:500 dilution. HIER: steam section in pH6 citrate buffer for 20 min and allow to cool prior to staining.
Availability 1-3 business days
Species Reactivity Human
Predicted Reactivity Mouse
Format Purified
Clonality Recombinant Rabbit Monoclonal
Isotype Rabbit IgG
Clone Name RM308
Purity Protein A purified from animal origin-free supernatant
UniProt P15056
Localization Cytoplasmic
Applications Immunohistochemistry (FFPE) : 1:200-1:500
Western Blot : 1:100-1:200
Limitations This recombinant BRAF antibody is available for research use only.
Review this product on BioCompare and get a $20 Amazon gift card

Related Products


This antibody reacts to human serine/threonine-protein kinase B-raf (BRAF). It may also react to mouse B-raf, as predicted by immunogen homology.

Application Notes

The stated application concentrations are suggested starting points. Titration of the recombinant BRAF antibody may be required due to differences in protocols and secondary/substrate sensitivity.


A peptide corresponding to the residues near N-terminus of human B-raf was used as the immunogen for the recombinant BRAF antibody.


Store the recombinant BRAF antibody at -20oC.

Bulk Quote Request Form
Phone Number*:
Catalog No.*:
Comments and Specifics(amount, formulation, etc.)*:
Validation code: Captchapackage Image

Can't read the image? click here to refresh.
    *required field

Your bulk quote request has been submitted successfully!

Please contact us if you have any questions.